title: Adverse event reporting in oncology clinical trials - lost in translation?
authors.affiliation: a Penn Medicine at Lancaster General Health , Ann B Barshinger Cancer Institute , Lancaster , PA , USA.
authors.forename: Shanthi
authors.initials: S
authors.lastname: Sivendran
authors.affiliation: b Mount Sinai School of Medicine , Tisch Cancer Institute , New York , NY , USA.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents
keywords: Adverse event; CONSORT; attribution; harms; patient reported outcomes